AtomVie Global Radiopharma Inc.
Website to be confirmed.
About AtomVie Global Radiopharma Inc.
AtomVie Global Radiopharma Inc. sits in Radiopharma Developer, a segment Bracken sees as structurally important to the radiopharma value chain.
Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.
What we're seeing
- Reuters Health · 2026-05-28Atomvie Global Radiopharma Inc expands cyclotron capacity to meet Lu-177 demandThe work builds on more than a decade of radiochemistry collaboration.
- Endpoints News · 2026-10-07Atomvie Global Radiopharma Inc announces Phase II readout for lead theranostic candidateIndustry observers expect more activity of this kind in the run-up to SNMMI 2026.
- FierceBiotech · 2026-03-02Atomvie Global Radiopharma Inc appoints new Chief Medical Officer ahead of pivotal trialIndustry observers expect more activity of this kind in the run-up to SNMMI 2026.
- BioPharma Reporter · 2026-04-25Atomvie Global Radiopharma Inc signs supply agreement to support late-stage trialsCoverage notes the company's growing footprint in the radioligand therapy space.
- Imaging Wire · 2026-09-16Atomvie Global Radiopharma Inc closes Series C round to scale radiopharma manufacturingIndustry observers expect more activity of this kind in the run-up to SNMMI 2026.
Mocked while we wire the Exa integration. Headlines are illustrative.
What we expect to see at the booth
Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.
A short Bracken POV will go here, drawing on our experience across this part of the radiopharma value chain. Specific commentary to be filled in by the team.
Editorial shown for exhibitors in Bracken's wheelhouse: radiopharma developers, isotope supply, CDMO/CMO, cyclotron, and imaging equipment.
Companies you may also want to visit.
Actinium Pharmaceuticals
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Actinium Pharmaceuticals.
View profile →Bayer Oncology
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Bayer Oncology.
View profile →BRACCO
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on BRACCO.
View profile →